L2 β-lactamase contributes to ceftolozane-tazobactam resistance in Pseudomonas aeruginosa
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.00356-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Preeti Garai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Tazobactam, beta-Lactamases, Cephalosporins. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The prevalence of non-susceptibility to ceftolozane-tazobactam (C/T) among Pseudomonas aeruginosa remains low, but novel mechanisms of C/T resistance are of concern. Herein, we describe a novel P. aeruginosa genotype associated with high-level C/T resistance (>256/4 µg/mL) in a single patient. Whole-genome sequencing of the isolate was compared to that of a susceptible isolate cultured from the same patient 2 months earlier. Analysis of the sequences revealed two different P. aeruginosa high-risk clones: sequence type (ST)111 followed by ST235. The C/T-resistant ST235 isolate contained five copies of a genetic element composed of an L2 β-lactamase gene ( bla L2 ) and a truncated ampR L2 transcriptional regulator gene, which are commonly found together in Stenotrophomonas maltophilia strains and have not been reported to mediate resistance to C/T. Comparative genomic analysis with other P. aeruginosa isolates failed to identify alternative explanations for the observed C/T resistance. We found that exogenous expression of bla L2 increased C/T minimum inhibitory concentrations (MICs) in genetically distinct P. aeruginosa strains. A screen of our archived isolates identified two P. aeruginosa clinical isolates, PS2045 and PS2046, with one and two copies, respectively, of the genetic element containing bla L2 and truncated ampR L2 . Interestingly, disruption of the gene bla L2 but not the truncated ampR L2 in PS2045 led to a decrease in C/T MIC. Thus, we report a novel mechanism of C/T resistance in P. aeruginosa partially mediated by an L2 β-lactamase independently of its canonical regulator, AmpR L2 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
- Midwestern University College of Pharmacy, Downers Grove Campus, Downers Grove, Illinois, USA.
- Department of Pharmacy, Northwestern Medicine, Chicago, Illinois, USA.
- Stanford University School of Medicine, Stanford, California, USA.
- Infectious Diseases, University of California Irvine, Orange, California, USA.
- Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
ORCID-Profile: Preeti Garai, Sophia H Nozick, Hannah Nam, J Nicholas O'Donnell, Egon A Ozer, Alan R Hauser, Nathaniel J Rhodes
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Garai, P., Nozick, S. H., Jozefczyk, C. C., Nam, H., O'Donnell, J. N., Ozer, E. A., Hauser, A. R., & Rhodes, N. J. (2026). L2 β-lactamase contributes to ceftolozane-tazobactam resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00356-26
Vancouver
Garai P, Nozick SH, Jozefczyk CC, Nam H, O'Donnell JN, Ozer EA, et al. L2 β-lactamase contributes to ceftolozane-tazobactam resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00356-26
BibTeX
@article{Garai2026,
author = {Garai, Preeti and Nozick, Sophia H and Jozefczyk, Caroline C and Nam, Hannah and O'Donnell, J Nicholas and Ozer, Egon A and Hauser, Alan R and Rhodes, Nathaniel J},
title = {L2 β-lactamase contributes to ceftolozane-tazobactam resistance in Pseudomonas aeruginosa},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.00356-26}
}
EUVIMED